Oncology Contact Us

Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Findings from the phase 3 CARTITUDE-4 study support the supplemental biologics license application for ciltacabtagene autoleucel in the treatment of relapsed/refractory multiple myeloma.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Targeting apoptosis in BRAF V600-mutated melanoma may be considered for future exploration in the post immunotherapy setting, according to an expert at Moffitt Cancer Center.

Sotorasib maintains a progression-free survival benefit compared with docetaxel in the treatment of patients with KRAS G12C-mutated non–small cell lung cancer in the phase 3 CodeBreaK 200 trial.